GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Cytori Therapeutics Inc (CYTX) [hlAlert]

Rating:
Buy CYTX
down 91.30 %

Cytori Therapeutics Inc (CYTX) rated Buy with price target $6 by Maxim Group

Posted on: Thursday,  Dec 11, 2014  8:25 AM ET by Maxim Group

Maxim Group rated Buy Cytori Therapeutics Inc (NASDAQ: CYTX) on 12/11/2014. Previously Maxim Group rated Buy Cytori Therapeutics Inc (NASDAQ: CYTX) on
09/07/2012., when the stock price was $3.45. Since then, Cytori Therapeutics Inc has lost 91.30% as of 09/08/2015's recent price of $0.30.
If you would have followed the previous Maxim Group's recommendation on CYTX, you would have lost 91.3% of your investment in 1096 days.

Cytori Therapeutics, Inc. develops, manufactures, and sells medical technologies to enable the practice of regenerative medicine. The Company?s commercial activities are focused on cosmetic and reconstructive surgery in Europe and Asia-Pacific, and stem and regenerative cell banking (cell preservation) in worldwide. Its product pipeline includes the development of new treatments for cardiovascular disease, spinal disc degeneration, gastrointestinal disorders, liver and renal disease and pelvic health conditions. The Company?s Celution System family of products processes patients? cells at the bedside in real time. During the year ended December 31, 2008, the Celution 800/CRS System was introduced into the European cosmetic and reconstructive surgery market through a network of medical distributors. The Celution 900/MB is marketed in Japan through its commercialization partner, Green Hospital Supply, Inc.

At Maxim Group, our vision for equity research is to be a client’s first call for value-added research on companies not widely followed by Wall Street. Maxim’s premier niche is emerging-growth companies in a variety of sectors, including healthcare, technology, retail and others. As strong believers in fundamental research, our analysts utilize a “bottom up” approach to making investment recommendations. We combine rigorous financial analysis of specific companies and industries with due diligence that includes frequent consults with suppliers, customers, competitors and senior management. By applying these skills and techniques, we are able to offer our clients differentiated research.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/11/2014 8:25 AM Buy
None
0.50 6.00
as of 10/17/2014
1 Week up  8.69 %
1 Month down  -50.98 %
3 Months down  -75.49 %
1 YTD down  -80.54 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/10/2014 11:25 AM Buy
None
0.52 6.00
9/7/2012 12:25 PM Buy
None
3.45 10.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy